Please ensure Javascript is enabled for purposes of website accessibility
Maxx Chatsko

Maxx Chatsko


Maxx has been a contributor to since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.

Recent articles

dude pointing up

Gold Stocks Continue Run Following Bullish Analyst Report

Is gold really headed to $3,000 per ounce?

410 binoculars kid

The Worst Mistake Amyris Investors Can Make Right Now

The company might have mobilized to respond to the coronavirus pandemic, but investors must focus on whether that results in tangible business progress.

stock down erased chalkboard

Shares of VBI Vaccines Tumble on Public Offering

The vaccine developer was forced to raise cash at a relatively low offering price, which will result in a significant amount of dilution.

arrow up shelves

Shares of BioNTech Soar on a Coronavirus Vaccine Announcement

The biotech and its partner, Pfizer, will soon begin the first clinical trials of a coronavirus vaccine in Germany.

600 scientist microscope

Gilead Sciences Races to Manufacture Remdesivir, but Chemistry Has Speed Limits

The biotech is racing to produce remdesivir for as many COVID-19 patients as possible. Will it be enough?

335 coal mining

Can U.S. Coal-Fired Power Plants Survive the Coronavirus Pandemic?

The EIA projects electricity generation from U.S. coal-fired power plants in 2020 will fall to 60-year lows.

600 businessman winning

2 High-Risk, High-Reward Stocks to Add to Your Watch List

These two businesses offer compelling growth potential, but one has yet to deliver on its promise and the other just became more complicated thanks to the coronavirus pandemic.

worker transmission grid

Electricity Demand in 2020 to Decline By Most Since Great Recession

The EIA expects this to be a rough year for the U.S. power sector, although there will be one bright spot: renewable energy.

152 building blocks stairs

2 Stocks to Start Investing in 2020

These utilities won't be spared by the coronavirus pandemic, but they're among the best investments for investors with a long-term mindset.

multiple lines up

Here's Why New Gold Jumped as Much as 13% Today

Increasing economic uncertainty has propped up gold prices.

433 money grab

Don't Waste Your Money on Penny Stocks, These 2 Stocks Are Better Buys

These healthcare stocks are risky, but they offer investors much better wealth-building potential than penny stocks.

376 DNA model teach

1 Recent IPO to Add to Your Watch List

This biotech is seeking to understand the immune system to develop insights and drug products for the most vexing health problems, including COVID-19.

stock down erased chalkboard

Athersys Stock Tumbles as Much as 27.7% on a Public Offering

The stem cell developer decided to wisely take advantage of a soaring share price to raise funds.

stock down finger

Alliance Resource Partners Tumbled as Much as 18.3% Today

The coal producer has taken steps to limit the impact of COVID-19 to its business, but investors remain cautious.

564 competition

2 Top Small-Cap Stocks to Buy Right Now

These development-stage drug companies are well positioned for success, even amid the current market uncertainty.

220 is a buy

Near a 2-Year Low, Is Codexis Stock a Buy?

The small-cap stock has been cut in half in the last year. Is a $650 million market cap too good to pass up?

multiple lines up

Invitae Gained as Much as 11.8% Today, but It Might Not Last

Investors might want to be cautious until the medical genetics company issues first-quarter 2020 operating results.

081 dog head tilted

Are There Any Safe Stocks to Buy?

One animal-health leader will help essential businesses and pet owners keep their creatures safe during these uncertain times.

business growth

Gold Stocks Are Soaring (Again) on Gloomy Economic Data

Precious metals are gaining on the latest jobs data. Gold and silver stocks are rising with them, but can the gains prove sustainable?

stock bar chart down

Why Fate Therapeutics Tumbled 23.9% in March

The development-stage pharma company gave up a good chunk of its gains from recent months, but roared back in April.